Targeting of Cisplatin-Resistant Melanoma Using a Multivalent Ligand Presenting an Elastin-like Polypeptide

• Published in: ACS biomaterials science & engineering 2020-09, Vol.6 (9), p.5024-5031
• Main Authors: Cheon, Sun-Ha, Seo, Bo-Yeon, Lee, Young-Jin, Sim, Dahye, Lee, Seon-Boon, Guruprasath, Padmanaban, Singh, Thoudam Debraj, Lee, Byung-Heon, Sarangthem, Vijaya, Park, Rang-Woon
• Format: Article
• Language: English
• Subjects: Animals; Cisplatin - pharmacology; Controlled Release and Delivery Systems; Elastin - genetics; Ligands; Melanoma - drug therapy; Mice; Peptides
• ISSN: 2373-9878; 2373-9878
• DOI: 10.1021/acsbiomaterials.0c00599

Acquired drug resistance is a common occurrence and the main cause of melanoma treatment failure. Melanoma cells frequently developed resistance against cisplatin during chemotherapy, and thus, targeting delivery systems have been devised to decrease drug resistance, increase therapeutic efficacy, and reduce side effects. We genetically engineered a macromolecular carrier using the recursive directional ligation method that specifically targets cisplatin-resistant (Cis-R) melanoma. This carrier is composed of an elastin-like polypeptide (ELP) and multiple copies of Cis-R melanoma-targeting ligands (M-peptide). The designed M16E108 contains 16 targeting ligands incorporated within an ELP and has an ideal thermal phase transition at 39 °C. When treated to melanoma cells, M16E108 specifically accumulated in Cis-R B16F10 melanoma cells and accumulated to a lesser extent in parental B16F10 cells. Consistently, M16E108 exhibited efficient homing and longer retention in tumor tissues in Cis-R melanoma-bearing mice than in parental B16F10 melanoma-bearing mice. Thus, M16E108 was found to display considerable potential as a novel agent that specifically targets cisplatin-resistant melanoma.